C4 Therapeutics earnings were -$103.8M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest CCCC earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$25.1M, up 22.7% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CCCC reported annual earnings of -$105.0M, with -0.3% growth.
What were C4 Therapeutics's earnings last quarter?
On CCCC's earnings call on Invalid Date, C4 Therapeutics (NASDAQ: CCCC) reported Q1 2026 earnings per share (EPS) of -$0.20, up 45.95% year over year. Total CCCC earnings for the quarter were -$25.13 million. In the same quarter last year, C4 Therapeutics's earnings per share (EPS) was -$0.37.
As of the last C4 Therapeutics earnings report, C4 Therapeutics is currently losing money. C4 Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$103.80 million, a 0.51% increase year over year.
What was CCCC's earnings growth in the past year?
As of C4 Therapeutics's earnings date in Invalid Date, C4 Therapeutics's earnings has grown year over year. CCCC earnings in the past year totalled -$103.80 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.